RCKT Insider Trading
Insider Ownership Percentage: 28.50%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $2,817,538.50
Rocket Pharmaceuticals Insider Trading History Chart
This chart shows the insider buying and selling history at Rocket Pharmaceuticals by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Rocket Pharmaceuticals Share Price & Price History
Current Price: $7.59
Price Change: ▼ Price Decrease of -0.29 (-3.68%)
As of 03/28/2025 05:00 PM ET
Rocket Pharmaceuticals Insider Trading History
Rocket Pharmaceuticals Institutional Trading History
Data available starting January 2016
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
Read More on Rocket Pharmaceuticals
Volume
1,094,321 shs
Average Volume
1,043,648 shs
Market Capitalization
$809.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.03
Who are the company insiders with the largest holdings of Rocket Pharmaceuticals?
Who are the major institutional investors of Rocket Pharmaceuticals?
Which major investors are selling Rocket Pharmaceuticals stock?
Within the last quarter, RCKT stock was sold by these institutional investors:
- Franklin Resources Inc.
- Millennium Management LLC
- Bamco Inc. NY
- Alliancebernstein L.P.
- Bank of America Corp DE
- Dimensional Fund Advisors LP
- Jane Street Group LLC
- EFG Asset Management North America Corp.
During the previous year, company insiders that have sold Rocket Pharmaceuticals company stock include:
- Gotham Makker (Director)
- Gaurav Shah (CEO)
- Kinnari Patel (Insider)
- David P Southwell (Director)
- Mark Andrew White (Insider)
Learn More investors selling Rocket Pharmaceuticals stock.
Which major investors are buying Rocket Pharmaceuticals stock?
In the previous quarter, RCKT stock was acquired by institutional investors including:
- Wellington Management Group LLP
- Suvretta Capital Management LLC
- Janus Henderson Group PLC
- Point72 Asset Management L.P.
- Boxer Capital Management LLC
- Avoro Capital Advisors LLC
- Toronto Dominion Bank
- Toronto Dominion Bank
